SynthesisDrugs2013
Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials.
Synthesis in Drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 9 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Efficacy and safety of reduced-dose versus full-dose DOACs in extended treatment of VTE: A systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2026Pooled it
- Duration of primary/secondary treatment to prevent recurrent venous thromboembolism: a systematic review and meta-analysis.Blood advances · 2025Pooled it
- Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism.The Cochrane database of systematic reviews · 2023Pooled it
- Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis.The Cochrane database of systematic reviews · 2023Pooled it
- American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.Blood advances · 2021Guideline
- American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.Blood advances · 2020Guideline
- Pooled it
- Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.The Cochrane database of systematic reviews · 2015Pooled it
- Pooled it
- The Aftermath of Pulmonary Embolism: Are Residual Thrombi Clinically Significant?Diagnostics (Basel, Switzerland) · 2025Review
- Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism.JAMA network open · 2023Article
- Effectiveness and Safety of Oral Anticoagulants in the Treatment of Acute Venous Thromboembolism: A Nationwide Comparative Cohort Study in France.Thrombosis and haemostasis · 2022Observational
- Article
- Article
- Primary prophylaxis of venous thromboembolic disease with direct oral anticoagulants in patients with severe inherited thrombophilia.Research and practice in thrombosis and haemostasis · 2021Article
- Management of antithrombotic therapy in gray areas of venous thromboembolism: a Delphi consensus panel.Internal and emergency medicine · 2020Article
- Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.Blood transfusion = Trasfusione del sangue · 2020Review
- Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism.Internal and emergency medicine · 2016Article
- Adverse cardiovascular events in acute coronary syndrome with indications for anticoagulation.Therapeutic advances in cardiovascular disease · 2016Article
- [Aspirin and venous thromboses].Der Internist · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCurrently available anticoagulants have limitations for long term treatment of venous thromboembolism (VTE).
objectiveA meta-analysis was performed to evaluate the efficacy and safety of new oral anticoagulants (NOACs) for extended treatment of VTE.
methodsPubMed, Cochrane Library, EMBASE, Web of Science and CINAHL databases were searched from January 01, 2001 through February 28, 2013. Randomized controlled trials (RCTs) comparing NOACs (apixaban, rivaroxaban and dabigatran) with placebo or warfarin for extended treatment of VTE were selected. Primary efficacy outcome was recurrent VTE or VTE related death, and primary safety outcome was major bleeding. We used random-effects models.
resultsFour RCTs included 7,877 participants. NOACs significantly lowered the risk of recurrent VTE or VTE-related death compared to placebo/warfarin (odds ratio [OR] 0.25, 95 % confidence interval [CI] 0.07 to 0.86; number needed to treat [NNT] = 30). All-cause mortality was significantly lower in NOACs group compared to placebo (OR 0.38, 95 % CI 0.18 to 0.80). Risk of major bleeding was not different with NOACs compared to placebo/warfarin (OR 0.88, 95 % CI 0.27 to 2.91). However, NOACs caused significantly higher rate of major or clinically relevant bleeding compared to placebo (OR 2.69, 95 % CI 1.25 to 5.77; number needed to harm [NNH] = 39). All three NOACs (apixaban, rivaroxaban and dabigatran) individually significantly reduced recurrent VTE or VTE-related death compared to placebo. Major or clinically relevant bleeding was higher with dabigatran and rivaroxaban but not with apixaban.
conclusionNOACs are effective for the extended treatment of venous thromboembolism and may reduce the risk of all-cause mortality. Dabigatran and rivaroxaban may cause more major or clinically relevant bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.